natgillin/translations-raw huggingface dataset:
Limited information from clinical trials suggests that the safety profile of Fabrazyme treatment in paediatric patients ages 5-7, treated with either 0.5 mg/kg every 2 weeks or 1.0 mg/kg every 4 weeks is similar to that of patients (above the age of 7) treated at 1.0 mg/kg every 2 weeks. 
Malobrojni podaci iz kliničkih ispitivanja upućuju da je sigurnosni profil liječenja lijekom Fabrazyme u pedijatrijskih bolesnika u dobi od 5 do 7 godina liječenih dozom od 0,5 mg/kg svaka 2 tjedna ili dozom od
Incidence of adverse reactions with Fabrazyme treatment System organ class 
Incidencija nuspojava kod liječenja lijekom Fabrazyme Organski sustav Vrlo često Često
Fabrazyme 35 mg powder for concentrate for solution for infusion Fabrazyme 5 mg powder for concentrate for solution for infusion 
Fabrazyme 35 mg prašak za koncentrat za otopinu za infuziju Fabrazyme 5 mg prašak za koncentrat za otopinu za infuziju
• itching eyes 
• svrbež očiju
The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of α-galactosidase A. 
Niz aminokiselina rekombinantnog oblika, kao i niz nukleotida koji ga kodira,
Very common Common 
Manje često
Gastrointestinal Disorders nausea, vomiting abdominal pain, abdominal pain upper, abdominal discomfort, stomach discomfort, hypoaesthesia oral, diarrhoea dyspepsia, dysphagia -- 
Poremećaji probavnog sustava mučnina, povraćanje bol u abdomenu, bol u gornjem dijelu abdomena, nelagoda u abdomenu, nelagoda u želucu, oralna hipoestezija, proljev dispepsija, disfagija --
Use of Fabrazyme during breastfeeding is not recommended. 
Ne preporučuje se primjena lijeka Fabrazyme tijekom dojenja.
• red rash 
• crveni osip
Patients experiencing mild or moderate infusion-associated reactions when treated with agalsidase beta during clinical trials have continued therapy after a reduction in the infusion rate (~0.15 mg/min; 10 mg/hr) and/or pre-treatment with antihistamines, paracetamol, ibuprofen and/or corticosteroids. 
(~0,15 mg/min; 10 mg/sat) i/ili prethodne primjene antihistaminika, paracetamola, ibuprofena i/ili kortikosteroida.
Respiratory, thoracic and mediastinal disorders dyspnoea, nasal congestion, throat tightness, wheezing, cough, dyspnoea exacerbated bronchospasm, pharyngolaryngeal pain, rhinnorhoea, tachypnoea, upper respiratory tract congestion hypoxia 
Poremećaji dišnog sustava, prsišta i sredoprsja dispneja, kongestija nosa, stezanje u grlu, piskanje pri disanju, kašalj, egzacerbacija dispneje bronhospazam, faringolaringealna bol, rinoreja, tahipneja, kongestija gornjeg dišnog sustava hipoksija
Skin and subcutaneous tissue disorders pruritus, urticaria, rash, erythema, pruritus generalized, angioneurotic oedema, swelling face, rash maculo-papular livedo reticularis, rash erythematous, rash pruritic, skin discolouration, skin discomfort leukocytoclastic vasculitis 
Poremećaji kože i potkožnog tkiva pruritus, urtikarija, osip, eritem, generalizirani pruritus, angioneurotski edem, oticanje lica, makulopapularni osip retikularni livedo, eritematozni osip,
- The active substance is agalsidase beta, one vial contains 35 mg. - The other ingredients are: 
- Djelatna tvar je agalzidaza beta, jedna bočica sadrži 35 mg.
Any unused solution should be discarded. 
Neupotrijebljena otopina mora se zbrinuti.
Musculoskeletal and connective tissue disorders pain in extremity, myalgia, back pain, muscle spasms, arthralgia, muscle tightness, musculoskeletal stiffness musculoskeletal pain -- 
bol u leđima, grčevi u mišićima, artralgija, stezanje u mišićima, mišićno-koštana ukočenost mišićno-koštana bol --
Fabrazyme 35 mg powder for concentrate for solution for infusion Reconstitute each vial of Fabrazyme 35 mg with 7.2 ml water for injections. 
Fabrazyme 35 mg prašak za koncentrat za otopinu za infuziju Jednu bočicu lijeka Fabrazyme od 35 mg rekonstituirajte sa 7,2 ml vode za injekcije.
Prior to adding the reconstituted volume of Fabrazyme required for the patient dose, it is recommended to remove an equal volume of 0.9% sodium chloride intravenous solution, from the infusion bag. 
Prije dodavanja rekonstituiranog volumena lijeka Fabrazyme potrebnog za dozu za bolesnika, preporučuje se iz infuzijske vrećice ukloniti jednaki volumen 0,9% otopine natrijevog klorida za intravensku primjenu.
It is recommended to administer the diluted solution through an in-line low protein-binding 0.2 µm filter to remove any protein particles which will not lead to any loss of agalsidase beta activity. 
Da bi se uklonile čestice proteina preporučuje se razrijeđenu otopinu primjenjivati kroz “in-line” filtar male sposobnosti vezanja proteina s porama veličine 0,2 µm.
Common (may affect up to 1 in 10 people): • chest pain 
Česte (mogu se javiti u manje od 1 na 10 osoba):
Fabrazyme 5 mg powder for concentrate for solution for infusion Reconstitute each vial of Fabrazyme 5 mg with 1.1 ml water for injections. 
Fabrazyme 5 mg prašak za koncentrat za otopinu za infuziju Jednu bočicu lijeka Fabrazyme od 5 mg rekonstituirajte s 1,1 ml vode za injekcije.
• skin discoloration 
• promjena boje kože
However, at the lower dose, IgG antibodies may play a role with respect to GL-3 clearance in some patients. 
IgG protutijela mogu utjecati na klirens GL-3.
In this trial, the initial rechallenge administration was at a low dose and a lower infusion rate (1/2 the therapeutic dose at 1/25 the initial standard recommended rate). 
(1/2 terapijske doze uz 1/25 početne standardne preporučene brzine).
• difficulty in breathing 
• otežano disanje
Reconstitute each vial of Fabrazyme 35 mg with 7.2 ml water for injections. 
Jednu bočicu lijeka Fabrazyme od 35 mg rekonstituirajte sa 7,2 ml vode za injekcije.
• burning sensation 
• osjećaj žarenja
• urticaria 
• koprivnjača
The rationale for enzyme replacement therapy is to restore a level of enzymatic activity sufficient to clear the accumulating substrate in the organ tissues; thereby, preventing, stabilizing or reversing the progressive decline in function of these organs before irreversible damage has occurred. 
Time se sprječava, stabilizira ili popravlja progresivno smanjenje funkcije tih organa prije nastanka nepopravljivih oštećenja.
• feeling hot 
• navala vrućine
- The active substance is agalsidase beta, one vial contains 5 mg. - The other ingredients are: 
- Djelatna tvar je agalzidaza beta, jedna bočica sadrži 5 mg.
Reconstitute each vial of Fabrazyme 5 mg with 1.1 ml water for injections. 
Jednu bočicu lijeka Fabrazyme od 5 mg rekonstituirajte s 1,1 ml vode za injekcije.
• injection site blood clotting 
• zgrušavanje krvi na mjestu primjene injekcije
Intravenous use. 
Za primjenu u venu.
5 vials of powder for concentrate for solution for infusion. 
5 bočica s praškom za koncentrat za otopinu za infuziju.
Fabrazyme 35 mg powder for concentrate for solution for infusion agalsidase beta 
Fabrazyme 35 mg prašak za koncentrat za otopinu za infuziju agalzidaza beta
Fabrazyme 35 mg powder for concentrate for solution for infusion Fabrazyme 35 mg is supplied in clear Type I glass 20 ml vials. 
Fabrazyme 35 mg je dostupan u prozirnim staklenim bočicama od 20 ml (staklo tipa I).
10 vials of powder for concentrate for solution for infusion. 
10 bočica s praškom za koncentrat za otopinu za infuziju.
• (mottled purplish) skin discoloration 
• promjena boje kože (ljubičaste šare)
Nervous system disorders headache, paraesthesia dizziness, somnolence, hypoaesthesia, burning sensation, lethargy, syncope hyperaesthesia, tremor 
hipoestezija, osjećaj žarenja, letargija, sinkopa hiperestezija, tremor --
No changes in dose are necessary for patients with kidney disease. 
U bolesnika s bolešću bubrega nije potrebno mijenjati dozu.
• lower blood oxygen levels • serious inflammation of the vessels 
• niže razine kisika u krvi
Fabrazyme 5 mg powder for concentrate for solution for infusion agalsidase beta 
Fabrazyme 5 mg prašak za koncentrat za otopinu za infuziju agalzidaza beta
• oedema 
• omaglica
Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of patients (see section 
U malog su broja bolesnika prijavljene reakcije koje upućuju na akutnu preosjetljivost (tipa I) (vidjeti dio 4.4).
• musculoskeletal stiffness 
• stezanje mišića
General disorders and administration site conditions chills, pyrexia, feeling cold fatigue, chest discomfort, feeling hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia feeling hot and cold, influenza-like illness, infusion site pain, infusion site reaction, injection site thrombosis, malaise, oedema 
osjećaj vrućine, periferni edem, bol, astenija, bol u prsištu, oticanje lica, hipertermija osjećaj vrućine i hladnoće, bolest nalik gripi, bol na mjestu primjene infuzije, reakcija na mjestu primjene infuzije, tromboza na mjestu injekcije, malaksalost, edem
Sodium phosphate monobasic, monohydrate Sodium phosphate dibasic, heptahydrate 
manitol natrijev dihidrogenfosfat hidrat natrijev hidrogenfosfat heptahidrat
Due to the limitations of the study design (small number of patients), no definitive conclusion regarding the dose maintenance regimen can be drawn, but these findings suggest that, after an initial debulking dose of 1.0 mg/kg every 2 weeks, 0.3 mg/kg every 2 weeks may be sufficient in some patients to maintain clearance of GL-3. 
Ipak, nalazi pokazuju da nakon početne doze od 1,0 mg/kg svaka 2 tjedna doza od 0,3 mg/kg svaka 2 tjedna može u nekih bolesnika biti dovoljna za održavanje klirensa GL-3.
Hepatic impairment Studies in patients with hepatic insufficiency have not been performed. 
Nisu provedena ispitivanja u bolesnika sa zatajivanjem jetre.
Ear and labyrinth disorders tinnitus, vertigo auricular swelling, ear pain 
Poremećaji uha i labirinta tinitus, vrtoglavica oticanje ušne školjke, bol u uhu
• increased heart beat 
• ubrzani otkucaji srca
Additional symptoms included mild or moderate dyspnoea, hypoxia (oxygen saturation decreased), throat tightness, chest discomfort, flushing, pruritus, urticaria, face oedema, angioneurotic oedema, rhinitis, bronchospasm, tachypnoea, wheezing, hypertension, hypotension, tachycardia, palpitations, abdominal pain, nausea, vomiting, infusion-related pain including pain at the extremities, myalgia, and headache. 
Ostali simptomi uključivali su blagu do umjerenu dispneju, hipoksiju (smanjenu saturaciju kisikom), stezanje u grlu, nelagodu u prsištu, crvenilo praćeno osjećajem užarenosti, pruritus, urtikariju, edem lica, angioneurotski edem, rinitis, bronhospazam,
Infusion of Fabrazyme at home may be considered for patients who are tolerating their infusions well. 
U bolesnika koji dobro podnose infuzije može se razmotriti mogućnost primjene infuzije lijeka Fabrazyme kod kuće.
• decreased blood pressure • hot flush 
• naglo oticanje lica ili grla • snižen krvni tlak
EU/1/01/188/004 1 vial of powder for concentrate for solution for infusion EU/1/01/188/005 5 vials of powder for concentrate for solution for infusion EU/1/01/188/006 10 vials of powder for concentrate for solution for infusion 
EU/1/01/188/004 1 bočica s praškom za koncentrat za otopinu za infuziju
Fabry disease 
FARMAKOLOŠKA SVOJSTVA
• sudden swelling of the face or throat 
• upala nosa ili ždrijela
• low heart rate 
• spori otkucaji srca
Fabrazyme 5 mg powder for concentrate for solution for infusion Fabrazyme 5 mg is supplied in clear Type I glass 5 ml vials. 
Fabrazyme 5 mg je dostupan u prozirnim staklenim bočicama od 5 ml (staklo tipa I).
In the postmarketing setting, experience was gained in patients who initiated treatment at a dose of 1 mg/kg every 2 weeks and subsequently received a reduced dose for an extended period. 
1 mg/kg svaka 2 tjedna, a nakon toga su dulje vrijeme primali smanjenu dozu.
Anaphylactoid reactions have been reported in the postmarketing setting. 
Nakon stavljanja lijeka u promet prijavljene su anafilaktičke reakcije.
- Necessary skills have to be acquired by non-healthcare professionals before Fabrazyme may be safely and effectively administered at home. - Their prescribing physician will provide training on the following elements: - That it is essential to follow strictly the prescribed dose and infusion rate - Method of preparation and administration of Fabrazyme - Instructions in handling possible adverse events - Instruction to seek emergency treatment by healthcare professionals in the event of any adverse reactions during an infusion 
- način pripreme i primjene lijeka Fabrazyme - upute za postupanje u slučaju mogućih nuspojava - bolesnika treba uputiti da potraži hitnu medicinsku pomoć u slučaju pojave nuspojava tijekom primjene infuzije
• rhinitis 
• nesvjestica
• upper respiratory tract congestion 
• opstrukcija gornjeg dijela dišnog sustava
Package leaflet: Information for the user Fabrazyme 5 mg powder for concentrate for solution for infusion 
Uputa o lijeku: Informacije za korisnika Fabrazyme 5 mg prašak za koncentrat za otopinu za infuziju agalzidaza beta
• musculoskeletal pain 
• ukočenost mišića i kostiju
Package leaflet: Information for the user Fabrazyme 35 mg powder for concentrate for solution for infusion 
Uputa o lijeku: Informacije za korisnika Fabrazyme 35 mg prašak za koncentrat za otopinu za infuziju agalzidaza beta
The level of support required for home infusion will be discussed and agreed by the patient and/or caregiver with the prescribing physician. 
Liječnik propisivač u dogovoru s bolesnikom i/ili njegovateljem određuje razinu potpore nužnu za primjenu infuzije kod kuće.
Agalsidase beta clearance was not influenced by weight in this population. 
U toj populaciji tjelesna težina nije utjecala na klirens agalzidaze beta.
Vascular disorders flushing, hypertension, pallor, hypotension, hot flush peripheral coldness -- 
tahipneju, piskanje pri disanju, hipertenziju, hipotenziju, tahikardiju, palpitacije, bol u abdomenu,
1 vial of powder for concentrate for solution for infusion. 
1 bočica s praškom za koncentrat za otopinu za infuziju.
• nasopharyngitis 
• grlobolja
• dizziness 
• bljedilo
The reconstituted solution contains 5 mg agalsidase beta per ml, and appears as a clear colourless solution. 
Rekonstituirana otopina je bistra, bezbojna otopina koja sadrži 5 mg agalzidaze beta po ml. pH vrijednost rekonstituirane otopine je otprilike 7,0.
• throat pain 
• bol u prsima
• malaise 
• vrtoglavica
• lethargy 
• proljev
• Summary of Product Characteristics and Package Leaflet 
• Sažetak opisa svojstava lijeka i Uputu o lijeku
Excipients: mannitol sodium phosphate monobasic, monohydrate sodium phosphate dibasic, heptahydrate See the leaflet for further information. 
Drugi sastojci su: manitol natrijev dihidrogenfosfat hidrat natrijev hidrogenfosfat heptahidrat
Genzyme Europe B.V.- NL Store in a refrigerator (2°C - 8°C) 
POSEBNE MJERE ČUVANJA Čuvati u hladnjaku (2°C - 8°C).
• redness 
• svrbež
• abdominal discomfort 
• prekomjerno suzenje
Elderly 
Trudnoća
• chest discomfort 
• bezvoljnost
Both cases resolved. 
Oba su slučaja bila uspješno riješena.
Older people (≥ 65 years) 
Starije osobe(≥ 65 godina)
This process is called remodelling. 
Taj se proces naziva preoblikovanje.
- if you are pregnant. 
- ako ste trudni. - ako dojite.
• Key signs and symptoms of serious adverse events 
• Ključni znakovi i simptomi ozbiljnih štetnih događaja
The infusion must be conducted according to standard medical practice. 
Infuzija se mora provoditi u skladu sa standardnom medicinskom praksom.
Tell your dentist immediately if you experience such symptoms. 
Odmah se obratite svom zubaru ako primijetite takve simptome.
The duration of the trial was one year. 
Ispitivanje je trajalo godinu dana.
Mutagenicity and carcinogenic potential 
Mutagenost i karcinogeni potencijal
The clinical relevance of these findings is unknown. 
Kliničko značenje tih nalaza nije poznato.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you. 
Pažljivo pročitajte cijelu uputu prije nego što počnete primati ovaj lijek jer sadrži Vama važne podatke.
Clinical experience with acute overdose is limited. 
Klinička iskustva s akutnim predoziranjem su ograničena.
Check with your doctor or nurse if you are not sure. 
Provjerite sa svojim liječnikom ili medicinskom sestrom ako niste sigurni.
- Do not throw away any medicines via wastewater (or household waste). 
Nikada nemojte nikakve lijekove bacati u otpadne vode (ili kućni otpad).
- The unopened bottle does not require any special storage conditions. 
- Neotvorena bočica ne zahtijeva posebne uvjete čuvanja.
All clinical fractures were verified based on the radiographic and/or clinical evidence. 
Svi klinički prijelom bili su potvrđeni na osnovi radiološkog i/ili kliničkog dokaza.
Your doctor will let you know when to return for your next dose. 
Vaš će Vam liječnik objasniti kada trebate primiti sljedeću dozu.
Effect on height 
Učinak na visinu
Clinical efficacy in men 
Klinička djelotvornost u muškaraca
This corresponds to a 28% reduction in the risk of all cause mortality (p=0.01). 
To se podudara s 28% smanjenjem rizika za sve uzroke smrtnosti (p=0,01).
Patients who have received doses higher than those recommended should be carefully monitored. 
Bolesnike koji su primali doze više od preporučenih potrebno je pažljivo pratiti.
Your doctor will inform you regarding the symptoms associated with hypocalcaemia. 
Liječnik će Vas upoznati sa simptomima koji su povezani s hipokalcijemijom.
- After opening the bottle, the product should be used immediately in order to avoid microbial contamination. 
- Nakon otvaranja bočice, lijek treba odmah primijeniti kako bi se izbjeglo mikrobiološko onečišćenje.
Follow carefully all instructions given to you by your doctor or nurse. 
Pažljivo slijedite sve upute koje Vam je dao liječnik ili medicinska sestra.
The infusion will take at least 15 minutes. 
Infuzija traje najmanje 15 minuta.
No symptomatic cases of hypocalcaemia were observed. 
Nisu opaženi simptomatski slučajevi hipokalcijemije.
It is important that you follow this advice carefully so that the level of calcium in your blood does not become too low in the period after the infusion. 
Važno je da se pažljivo pridržavate tog savjeta kako razina kalcija u krvi ne bi postala preniska u razdoblju nakon primjene infuzije.
The frequency of hypocalcaemia was much lower following subsequent infusions. 
Učestalost hipokalcijemije bila je znatno niža nakon daljnjih infuzija.
Class effects: 
Učinci klase:
2100 Gödöllő 
2100 Gödöllő Mađarska
A summary of results is presented in Table 3. 
Sažetak rezultata prikazan je u Tablici 3.
Zoledronic acid Teva Generics may work for longer than one year, and your doctor will let you know if you need to be treated again. 
Zoledronatna kiselina Teva Generics može djelovati duže od godinu dana, a liječnik će Vam reći ako se trebate ponovo liječiti.
• When to seek attention from the health care provider 
• Kada zatražiti pomoć zdravstvenog djelatnika
Limited data on re-treatment of Paget's disease are available (see section 5.1). 
Dostupni su samo ograničeni podaci o ponovnom liječenje Pagetove bolesti (vidjeti dio 5.1).
This is especially important in patients who take diuretics (“water pills”) and in elderly patients. 
To je osobito važno u bolesnika koji uzimaju diuretike („tablete za mokrenje“) i u starijih bolesnika.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: 
Za sve infromacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje u promet gotovog lijeka:
• Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non smoking and healthy diet 
• Potreba za primjerenim nadomještanjem kalcija i vitamina D, primjerenom fizičkom aktivnošću, nepušenjem i zdravom prehranom
Table 1 Infections and infestations 
Tablica 1. Infekcije i infestacije
Poor healing of these fractures has also been reported. 
Također je zabilježeno slabo zacjeljivanje tih prijeloma.
EXP After opening: 24 hours at 2°C - 8°C 
Nakon otvaranja: 24 sata na 2°C - 8°C
** Based on post-marketing reports. 
** Temeljeno na izvješćima poslije stavljanja u promet.
No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects. 
Dozu nije potrebno prilagođavati jer su bioraspoloživost, distribucija i eliminacija bili slični u starijih bolesnika i mlađih ispitanika.
In the HORIZON-RFT study 508 men were randomised into the study and 185 patients had BMD assessed at 24 months. 
U ispitivanju HORIZON-RFT randomizirano je 508 muškaraca i u 185 bolesnika BMD je bio procijenjen nakon 24 mjeseca.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. 
Zoledronatna kiselina bila je proučavana u štakora zbog potencijalnih štetnih učinaka na plodnost roditeljske i F1 generacije.
At the menopause, a woman's ovaries stop producing the female hormone oestrogen, which helps keep bones healthy. 
U menopauzi ženski jajnici prestaju stvarati ženski hormon estrogen koji pomaže u održavanju zdravih kostiju.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti, nuspojave su poredane prema padajućoj ozbiljnosti.
- if you have hypocalcaemia (this means that the levels of calcium in your blood are too low). 
- ako imate hipokalcijemiju (što znači da imate prenisku razinu kalcija u krvi).
The physician educational material should contain the following key elements: 
Edukativni materijali za liječnika trebaju sadržavati sljedeće ključne elemente:
These could be signs of bone damage in the jaw (osteonecrosis). 
To bi mogli biti znakovi oštećenja kostiju u čeljusti (osteonekroze).
Hypocalcaemia* Uncommon Anorexia, decreased appetite 
Hipokalcijemija * Manje često Anoreksija, smanjen apetit
The majority of patients continued to receive glucocorticoids for the one year duration of the trial. 
Većina bolesnika nastavila je primati glukokortikoide tijekom godine dana trajanja ispitivanja.
The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race or body weight. 
Ukupni klirens iz organizma je 5,04 ± 2,5 l/sat, neovisno o dozi i bez obzira na spol, dob, rasu i tjelesnu težinu.
At least one new vertebral fracture (0-1 year) At least one new vertebral fracture (0-2 year) At least one new vertebral fracture (0-3 year) ** p <0.0001 
Najmanje jedan novi vertebralni prijelom (0-1 godina) Najmanje jedan novi vertebralni prijelom (0-2 godine) Najmanje jedan novi vertebralni prijelom (0-3 godine) ** p <0,0001
Osteoporosis could also occur in men and women because of the long term use of steroids, which can affect the strength of bones. 
Osteoporoza se također može pojaviti u muškaraca i žena zbog dugotrajnog korištenja steroida koji utječu na čvrstoću kostiju.
Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects. 
Vaš liječnik će Vam preporučiti blagi lijek protiv bolova, poput ibuprofena ili paracetamola, kako bi se smanjile ove nuspojave.
It is especially important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration. 
Osobito je važno da Vaš liječnik zna za sve lijekove koje uzimate, naročito ako uzimate lijekove za koje je poznato da štetno djeluju na bubrege (npr. aminoglikozidi) ili ako uzimate diuretike (“tablete za mokrenje”) koji mogu uzrokovati dehidraciju.
Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions. 
Nuspojave povezane s prvom infuzijom su vrlo česte (javljaju se u više od 30% bolesnika), ali su znatno rjeđe nakon daljnjih infuzija.
Many of these patients had signs of local infection including osteomyelitis, and the majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. 
Mnogi od tih bolesnika imali su znakove lokalne infekcije uključujući osteomijelitis, a većina izvješća odnosi se na bolesnike s rakom nakon vađenja zubi ili drugih stomatoloških operacija.